Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SpaceX (SPCX) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

SpaceXTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs SpaceX — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while SpaceX trades at $139.01 (market cap $1.76T). The key difference: SpaceX is far larger — about 347.1× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.

	ACAD	SPCX
Market Cap	$5.07B	$1.76T
Sector	Health	Technology
52-Week High	$29.41	$202.09
52-Week Low	$20.06	$108.27
Enterprise Value	$4.19B	$1.70T

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

SpaceX

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACAD

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.PRNewsWire · 1 day agoBullish ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.Andrew Wynn · 2 days agoBullish View details →

SPCX

Norway's sovereign fund reveals $1.2B stake in SpaceX as stock nears IPO price.Finbold · 5 hours agoBullish SpaceX shares rebound near IPO price amid ambitious $1T revenue goal by 2030, but timeline seen as aggressive.24/7 Wall Street · 6 hours agoBullish SpaceX's AI revenue soars 247% YoY, set to dominate by Q3 with $300B potential by 2027Seeking Alpha · 6 hours agoBullish View details →

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.